rs13222385
|
|
|
0.010 |
GeneticVariation |
BEFREE |
SNPs in cancer genes including rs2159359 SNP in NME1 and rs13222385 in EGFR may stratify risk in EEC and are prioritized for further investigation.
|
30827726 |
2019 |
rs139429793
|
|
|
0.010 |
GeneticVariation |
BEFREE |
KRAS E63K is curated in the Catalogue of Somatic Mutations in Cancer database.
|
31289513 |
2019 |
rs748491031
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We detected the epidermal growth factor receptor L858R, MSH2 R929* and telomerase reverse transcriptase amplification in the lung cancer specimen; CDH1 c.1320+1G>T mutation in the gastric cancer (GC) specimen; and MLH1 c.1896+5G>A germline mutation in the lung and GC specimens by 450 cancer-related gene mutations detection using next-generation sequencing technology.
|
31207149 |
2019 |
rs556324078
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, we showed that the D717V, G800D, G800R, L840F, G843D, S925F, R1022Q, R1032Q, and S1100F VEGFR2 mutants promote tumor growth in mice.<b>Conclusions:</b> Our study supports WES-cfDNA as a powerful platform for portraying the somatic mutation landscape of cancer and discovery of new resistance mechanisms to cancer therapies.
|
29588308 |
2018 |
rs140516819
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Using NGS, the following mutations were detected: nonsense mutations in four tumor suppressor genes [APC R1114X (molecular argument that the cancer was a primary tumor of colon), TP53 R213X, RB1 E137X and FBWX7 R393X & S282X], mutations in three receptor tyrosine kinases (RET A919V of high transforming activity, EGFR E114K and FLT3 L601I) well known as oncogenes.
|
28730258 |
2017 |
rs35918369
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Using NGS, the following mutations were detected: nonsense mutations in four tumor suppressor genes [APC R1114X (molecular argument that the cancer was a primary tumor of colon), TP53 R213X, RB1 E137X and FBWX7 R393X & S282X], mutations in three receptor tyrosine kinases (RET A919V of high transforming activity, EGFR E114K and FLT3 L601I) well known as oncogenes.
|
28730258 |
2017 |
rs746763556
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Among these impactful variants are rare somatic, clinically actionable variants including EGFR S645C, ARAF S214C and S214F, ERBB2 S418T, and multiple BRAF variants, demonstrating that rare mutations can be functionally important in cancer.
|
27478040 |
2016 |
rs961150162
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The DDR2 E655K mutation can play a role in cancer progression by reducing the growth-inhibitory effect of collagen.Clin Cancer Res; 22(14); 3663-71.©2016 AACR.
|
26826182 |
2016 |
rs767505234
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our studies identify T725M and L861R as rare cancer-associated mutations inasmuch as these mutations increase EGFR activity in the absence of the activating EGF ligand in cell-based assays.
|
24743239 |
2014 |
rs1050171
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In exon 20, a variant from CAG to CAA at codon 787 (2361G-> A) was identified in 19 patients, which was a genomic variation of EGFR since it was found in both cancer tissue and white blood cells.
|
22252115 |
2012 |
rs987532315
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In exon 20, a variant from CAG to CAA at codon 787 (2361G-> A) was identified in 19 patients, which was a genomic variation of EGFR since it was found in both cancer tissue and white blood cells.
|
22252115 |
2012 |
rs121913444
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Two frequent cancer-driver mutation sequences (EGFR-L861Q, NRAS-Q61K) were tested.
|
29069899 |
2017 |
rs121913444
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our studies identify T725M and L861R as rare cancer-associated mutations inasmuch as these mutations increase EGFR activity in the absence of the activating EGF ligand in cell-based assays.
|
24743239 |
2014 |
rs1057519861
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Noteworthy effect of slight variation in aliphatic chain length of trisubstituted imidazole inhibitors against epidermal growth factor receptor L858R/T790M/C797S mutant in cancer therapy.
|
30582282 |
2019 |
rs1057519861
|
|
|
0.030 |
GeneticVariation |
BEFREE |
We also demonstrated that PE2988 cells, a C797S-independent osimertinib-resistant primary cancer cell line from a lung cancer patient, responded to combined AXL inhibitor and osimertinib treatment.
|
31162839 |
2019 |
rs1057519847
|
|
|
0.030 |
GeneticVariation |
BEFREE |
These conjugates exhibited high antiproliferative potency against a number of cancer cell lines, including the epidermal growth factor receptor (EGFR) L858R/T790M mutant cell.
|
28236592 |
2017 |
rs1057519848
|
|
|
0.030 |
GeneticVariation |
BEFREE |
These conjugates exhibited high antiproliferative potency against a number of cancer cell lines, including the epidermal growth factor receptor (EGFR) L858R/T790M mutant cell.
|
28236592 |
2017 |
rs1057519861
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The combination of a MEK inhibitor with AZD9291 restores the sensitivity of AZD9291-resistant cells including those with C797S mutation to undergo apoptosis and growth regression <i>in vitro</i> and <i>in vivo</i><b>Conclusions:</b> Modulation of MEK/ERK-dependent Bim and Mcl-1 degradation critically mediates sensitivity and resistance of EGFR-mutant NSCLC cells to AZD9291 and hence is an effective strategy to overcome acquired resistance to AZD9291.<i>Clin Cancer Res; 23(21); 6567-79.©2017 AACR</i>.
|
28765329 |
2017 |
rs121434568
|
|
|
0.030 |
GeneticVariation |
BEFREE |
These conjugates exhibited high antiproliferative potency against a number of cancer cell lines, including the epidermal growth factor receptor (EGFR) L858R/T790M mutant cell.
|
28236592 |
2017 |
rs1057519847
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The purpose of this study was to clarify the relationship between the EGFR-L858R mutation and cancer cell invasion ability and to investigate the molecular mechanisms involved in the formation of MPE.
|
26338423 |
2015 |
rs1057519848
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The purpose of this study was to clarify the relationship between the EGFR-L858R mutation and cancer cell invasion ability and to investigate the molecular mechanisms involved in the formation of MPE.
|
26338423 |
2015 |
rs121434568
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The purpose of this study was to clarify the relationship between the EGFR-L858R mutation and cancer cell invasion ability and to investigate the molecular mechanisms involved in the formation of MPE.
|
26338423 |
2015 |
rs1057519847
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The results of cancer tissue specimens were identical to those with existing systems (nucleic acid-locked nucleic acid PCR clamp or cycleave PCR), except for two samples that showed both exon 19 deletions and L858R.
|
22858585 |
2012 |
rs1057519848
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The results of cancer tissue specimens were identical to those with existing systems (nucleic acid-locked nucleic acid PCR clamp or cycleave PCR), except for two samples that showed both exon 19 deletions and L858R.
|
22858585 |
2012 |
rs121434568
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The results of cancer tissue specimens were identical to those with existing systems (nucleic acid-locked nucleic acid PCR clamp or cycleave PCR), except for two samples that showed both exon 19 deletions and L858R.
|
22858585 |
2012 |